Last reviewed · How we verify
aspirin discontinuation
Aspirin discontinuation is a clinical trial strategy that evaluates the effects of stopping aspirin therapy in patients who have been taking it for primary or secondary prevention.
Aspirin discontinuation is a clinical trial strategy that evaluates the effects of stopping aspirin therapy in patients who have been taking it for primary or secondary prevention. Used for Evaluation of aspirin discontinuation in patients on chronic aspirin therapy.
At a glance
| Generic name | aspirin discontinuation |
|---|---|
| Also known as | initiation of aspirin in early pregnancy |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is not a drug itself, but rather a clinical intervention studying what happens when aspirin is withdrawn. The trial likely examines whether discontinuation affects cardiovascular outcomes, bleeding risk, or other clinical parameters in specific patient populations. The mechanism being studied is the physiological response to removal of aspirin's antiplatelet effects.
Approved indications
- Evaluation of aspirin discontinuation in patients on chronic aspirin therapy
Common side effects
- Cardiovascular events (myocardial infarction, stroke)
- Bleeding reduction
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |